SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma soars on inking partnership with Credible Innovations

12 Jul 2023 Evaluate

Ajanta Pharma is currently trading at Rs. 1421.35, up by 20.70 points or 1.48% from its previous closing of Rs. 1400.65 on the BSE.

The scrip opened at Rs. 1424.95 and has touched a high and low of Rs. 1459.00 and Rs. 1408.30 respectively. So far 4170 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1550.00 on 22-Jun-2023 and a 52 week low of Rs. 1115.15 on 28-Oct-2022.

Last one week high and low of the scrip stood at Rs. 1459.00 and Rs. 1378.50 respectively. The current market cap of the company is Rs. 18005.94 crore.

The promoters holding in the company stood at 66.21%, while Institutions and Non-Institutions held 26.00% and 7.79% respectively.

Ajanta Pharma has entered into a global strategic partnership with Credible Innovations to improve its ESG reporting and achieve sustainability goals. Credible, headquartered in San Francisco, is an AI-powered ESG bookkeeping and reporting service provider. Through this partnership, Ajanta Pharma and Credible will collaborate to enhance their ESG data management and reporting capabilities for the Sustainability and BRSR Framework. 

This collaboration aims to improve sustainability practices and drive positive social and environmental impact within the pharmaceutical industry. With seven state-of-the-art manufacturing facilities, Ajanta Pharma provides quality medicines to over 30 countries. As part of its ESG goals, Ajanta Pharma actively monitors and reports on sustainability initiatives. The company has chosen Credible as its strategic and implementation partner to enhance its ESG performance by setting ambitious targets and implementing continuous improvement measures.

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.


Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×